
Jonathan James, CEO, Hope Charities, discusses how, despite policy advancements, millions of people still face barriers to healthcare access.

Jonathan James, CEO, Hope Charities, discusses how, despite policy advancements, millions of people still face barriers to healthcare access.

A Day 3 presentation dives into the impact of copay accumulators, maximizers, and AFPs on driving cost savings.

The latest news for pharma industry insiders.

Jonathan James, CEO, Hope Charities, discusses the challenge of nonprofits securing sustainable funding while ensuring patients are aware of available assistance.

The presentation suggests ways to educate patients on the options available to them, with the hope of ultimately improving health outcomes.

The latest news for pharma industry insiders.

Jonathan James, CEO, Hope Charities, discusses the critical importance of maintaining access to life-saving medications for patients with rare diseases to lead productive lives.

The session provides an overview of the uninsured population, and also tackles challenges faced by patients when it comes to accessing PAPs.

The latest news for pharma industry insiders.

A roundtable explores how patient access needs are being measured, while also discussing the value of affordability in decision-making.

Jonathan James, CEO, Hope Charities, discusses reimbursement challenges and barriers to care in patients requiring life-saving medications.

The conference’s first panel offers insight on the current state of awareness among beneficiaries of the Part D cap and Medicare Prescription Payment Plan via the PAN Foundation’s latest research.

The latest news for pharma industry insiders.

The conference’s opening session highlights the sector’s current landscape of healthcare coverage and access.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, outlines the ways that tariffs disrupt pharma supply chains, along with how leaders can evaluate and prepare for the resulting challenges.

The latest news for pharma industry insiders.

Why driving results from such strategies—amid industry disruption—will be critical to success.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, comments on how he envisions automation in the CAR-T manufacturing space playing a role in improving efficiency, reducing costs, and ultimately, expanding patient access.

The latest news for pharma industry insiders.

The thermal packaging company not only bolsters its APAC presence—it also grows its influence in the life sciences’ temperature-monitoring logistics sector.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, discusses how regulatory hurdles are impacting the advancement of CGTs, along with the changes he would like to see along that front in order to accelerate patient access.

The latest news for pharma industry insiders.

The CRDMO’s acquisition of the Baltimore plant is expected to boost its biologics presence.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, outlines the internal constraints that CFOs are reporting as their biggest manufacturing obstacle, along with other hurdles they are encountering.

The latest news for pharma industry insiders.

The partnership focuses on enhancing the patient experience by providing greater affordability and access to specialty meds.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, comments on the primary factors causing manufacturing bottlenecks in the space, along with how the industry can overcome them in order to scale up production.

The latest news for pharma industry insiders.

The updated tax on Canadian imports will rise from 25% to 50%, taking effect March 12.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, offers his perspective on the state of CGTs, along with their potential for transforming medicine.